- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Dr. Kornblum on Impact of PrECOG 0102 Trial for HR+/HER2- Breast Cancer
Noah S. Kornblum, MD, assistant professor of medicine, Albert Einstein College of Medicine, and attending physician of medicine, Montefiore-Einstein Center for Cancer Care, discusses the phase II PrECOG 0102 trial, which explored the addition of everolimus (Afinitor) to fulvestrant (Faslodex) as a treatment for patients with metastatic hormone receptor (HR)–positive, HER2-negative breast cancer.
Noah S. Kornblum, MD, assistant professor of medicine, Albert Einstein College of Medicine, and attending physician of medicine, Montefiore-Einstein Center for Cancer Care, discusses the phase II PrECOG 0102 trial, which explored the addition of everolimus (Afinitor) to fulvestrant (Faslodex) as a treatment for patients with metastatic hormone receptor (HR)—positive, HER2-negative breast cancer.
PrECOG 0102 was a randomized, double-blind, phase II study. Here, the everolimus/fulvestrant combination doubled median progression-free survival rates compared with fulvestrant alone, from 5.1 months on fulvestrant to 10.4 months with the combination (HR, 0.60; 95% CI, 0.40-0.92; P = .02).
The PI3k/Akt/mTOR pathway is usually a variant in aromatase inhibitor or endocrine resistant breast cancer in multiple ways, Kornblum explains. The logic behind the investigative regimen was to target the mTOR pathway with a mTOR inhibitor in combination with an established endocrine backbone, such as fulvestrant. Fulvestrant was chosen as it has more potent estrogen receptor-inhibitory activity than an agent such as exemestane.
<<<